From: Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
N | Primary prevention | Secondary prevention | ||||
---|---|---|---|---|---|---|
MACE | No MACE | p | MACE | No MACE | P | |
17 | 135 | 14 | 43 | |||
Metformin | 10 (58.82%) | 124 (91.85%) | 0.001 | 9 (64.29%) | 37 (86.05%) | 0.115 |
Pioglitazone | 0 | 30 (22.22%) | 0.042 | 0 | 4 (9.30%) | 0.563 |
Acarbose | 1 (5.88%) | 6 (4.44%) | 0.551 | 1 (7.14%) | 1 (2.33%) | 0.434 |
Sulfonylureas/meglitinides | 8 (47.06%) | 78 (57.78%) | 0.552 | 6 (42.86%) | 17 (40.48%) | 0.875 |
Insulin | 15/17 (88.24%) | 81 (60.00%) | 0.031 | 13 (92.86%) | 27 (62.79%) | 0.044 |
SGLT-2 inhibitors | 3 (17.65%) | 67 (49.63%) | 0.018 | 2 (14.29%) | 23 (53.49%) | 0.013 |
DPP-4 inhibitors | 2 (11.76%) | 37 (27.82%) | 0.240 | 5 (35.71%) | 17 (39.53%) | 0.705 |